The European Medicines Agency (EMA) has recommended approval for Novo Nordisk’s Wegovy oral pill, a once-daily 25-milligram semaglutide tablet for weight loss in adults with obesity or overweight conditions, potentially unlocking EU market access by late summer 2026. The decision follows a 67-day review period after the Committee for Medicinal Products for Human Use (CHMP) endorsed the drug on May 22, with the European Commission expected to finalize the ruling by July 2026.
Why Wegovy’s Pill Could Reshape Europe’s Weight-Loss Market
Wegovy’s transition from injectable to oral form marks a pivotal shift in Europe’s obesity treatment landscape. Unlike the weekly subcutaneous injections currently used for Wegovy (semaglutide 2.4 mg or 7.2 mg), the new tablet—approved in the U.S. since January 2026—offers a daily, non-invasive alternative for adults with obesity or overweight status complicated by conditions like type 2 diabetes or hypertension. The EMA’s recommendation positions Wegovy as the first oral GLP-1 receptor agonist specifically approved for weight management in Europe, giving Novo Nordisk a critical head start over competitors like Eli Lilly’s upcoming Foundayo (orforglipron), which isn’t expected in Europe until 2027.
According to the EMA’s CHMP, the decision hinges on data from Novo Nordisk’s OASIS-4 study, where participants achieved an average 16.6% weight loss over a year. Over one-third of participants lost at least 20% of their body weight, with the drug demonstrating efficacy in reducing cardiovascular risks—a key differentiator in Europe’s healthcare systems, where cost-effectiveness and long-term safety are scrutinized more rigorously than in the U.S.
The oral formulation’s arrival couldn’t come at a more strategic time for Novo Nordisk. While the company’s injectable Wegovy remains the preferred option in major U.S. pharmacy networks like CVS Caremark—despite Lilly’s Zepbound returning to the formulary in October 2026—the tablet’s EU approval could mitigate competitive pressure from Lilly’s oral GLP-1 agonists. In the U.S., Lilly’s Foundayo already faces headwinds: CVS lifted its market-exclusivity restrictions on June 1, 2026, allowing pharmacies to stock competing oral GLP-1 drugs. Europe’s delayed entry for Lilly’s oral options gives Novo Nordisk a temporary monopoly in a region where obesity-related healthcare costs are skyrocketing.
The EU’s 67-Day Review: A Timeline of Regulatory Hurdles
- May 22, 2026: EMA’s CHMP recommends approval for Wegovy’s 25 mg oral tablet and the high-dose 7.2 mg injectable, citing OASIS-4 study data showing 16.6% average weight loss.
- June 18, 2026: European Commission begins member-state consultations (standard 67-day process).
- July 2026 (target): Commission issues final approval, triggering EU-wide availability. Germany and other countries can then begin prescribing the drug, though reimbursement negotiations with insurers will follow separately.
- Third-quarter 2026: Novo Nordisk plans commercial launch in select European markets, with full rollout contingent on regulatory green lights.
The 67-day review window—mandated by EU regulations—reflects the bloc’s cautious approach to novel weight-loss drugs. Unlike the U.S., where the FDA’s accelerated pathways allowed Wegovy’s oral version to hit shelves in January 2026, Europe’s centralized process demands rigorous cross-border alignment. The delay also gives Novo Nordisk time to prepare for reimbursement battles: In Germany, for example, only 2% of eligible patients currently receive pharmaceutical weight-loss support, despite obesity affecting 20% of the adult population and contributing to 100,000 premature deaths annually.
Apotheken Umschau notes that the oral tablet’s approval could expand access to patients who struggle with injections, particularly those with needle phobia or logistical barriers. However, the drug’s cost remains a wild card. While the EMA’s recommendation doesn’t dictate pricing, Novo Nordisk’s U.S. list price for the oral Wegovy starts at $1,300 per month—far beyond what European health systems typically cover without prior authorization. The company’s stock, which has dipped 12.5% since January 2026 amid competition fears, could rebound if the EU approval spurs volume growth or secures favorable formulary placements.
Competition Heats Up: Lilly’s Delayed Entry and Novo Nordisk’s Stock Struggles
Novo Nordisk’s regulatory wins in Europe come as its U.S. market share faces pressure from Eli Lilly’s aggressive expansion. Lilly’s Foundayo, an oral GLP-1 agonist, secured U.S. FDA approval on April 1, 2026, and was added to CVS Caremark’s formulary on June 1, 2026—ending Wegovy’s exclusive status for oral therapies. While Wegovy (both injectable and oral) retains preferred-list status in CVS’s formulary, the loss of exclusivity has eroded Novo Nordisk’s pricing power. Analysts at Citi, while maintaining a “Neutral” rating on the stock, cite the EU approval as a potential catalyst for stability, given Europe’s slower adoption of Lilly’s oral alternatives.
Finanztrends highlights the financial stakes: Novo Nordisk’s stock trades at a 10.5x price-to-earnings ratio—well below its historical average of 26x—reflecting investor skepticism about its ability to sustain growth amid competition. The company’s RSI of 47.6 suggests neither overbought nor oversold conditions, but the upcoming ADA Diabetes Congress (June 5–8, 2026) in New Orleans could shift sentiment. Novo Nordisk plans to unveil Phase 3 data for CagriSema, a dual GLP-1/amylin agonist, and early-stage results for Zenagamtide (formerly Amycretin), both of which could redefine the obesity-treatment pipeline.
Yet the bigger question is whether Europe’s healthcare systems will follow the U.S. playbook. In Germany, for instance, only 60% of type 2 diabetes patients meet their HbA1c targets, and early weight loss of just 5% can significantly improve outcomes. With 9.3 million Germans living with diabetes and obesity rates climbing, the demand for effective treatments is undeniable—but reimbursement remains the bottleneck. If Wegovy’s oral version secures coverage, it could finally bridge the gap between medical need and access.
What’s Next: Medicare, Market Share, and the Race to Dominate GLP-1
The next 30 days will be critical for Novo Nordisk. The European Commission’s July decision will determine whether Wegovy’s oral pill hits shelves by summer, but the real inflection point may come from U.S. Medicare. Starting July 1, 2026, Medicare Part D plans are expected to cover obesity medications for a broader swath of beneficiaries—a policy shift that could double the addressable patient pool overnight. If Wegovy retains its formulary dominance in the U.S. while gaining early traction in Europe, Novo Nordisk could offset Lilly’s inroads by leveraging its dual pipeline: oral and injectable GLP-1 therapies.
Longer-term, the race to dominate the GLP-1 market hinges on three factors:
- Reimbursement: Europe’s patchwork of national healthcare systems will dictate adoption rates. Germany’s early access programs could set a precedent, but Southern European countries may resist high costs.
- Competition: Lilly’s Foundayo won’t arrive in Europe until 2027, but other players like Retrophin’s retatrutide (in development) could disrupt the market by 2028.
- Innovation: Novo Nordisk’s CagriSema and Zenagamtide could redefine the category if they prove superior to semaglutide in clinical trials. The ADA Congress data will be the first real test.
For now, the focus is on Europe. If the European Commission approves Wegovy’s oral pill by July, Novo Nordisk will have turned regulatory caution into a commercial advantage—at least for the next 12 months. The question is whether that’s enough to reverse its stock’s downward trajectory or if the GLP-1 gold rush has already peaked.
One thing is certain: The obesity-treatment market is no longer a niche. With 20% of Europe’s adult population classified as obese and diabetes rates rising, the stakes couldn’t be higher. For investors, patients, and policymakers alike, the next few months will reveal whether Wegovy’s pill can deliver on its promise—or if the real breakthrough is still to come.
